PEDIATRICS Vol. 72 No. 3 September 1983, pp. 416-419
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blombäck, M.
Right arrow Articles by Ritzén, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blombäck, M.
Right arrow Articles by Ritzén, E. M.

Estrogen Treatment of Tall Girls: Risk of Thrombosis?

Margareta Blombäck MD1, Kerstin Hall MD1, and E. Martin Ritzén MD1

1 From the Department of Blood Coagulation Disorders, Karolinska Institute; Department of Endocrinology and Pediatric Endocrinology Unit, Karolinska hospital; stockholm

In 34 girls who were treated with large doses of ethinylestradiol because of expected excessive tall stature, antithrombin activity in the blood was followed before, during, and after treatment. All girls showed lower levels of antithrombin during treatment than before or after estrogen administration; the mean concentration during treatment was at or below the lower limit of control values (-2 SD). In three girls, the antithrombin levels were so low that the medication was withdrawn. There was no difference between the mean levels of antithrombin activity in the three groups treated with 0.25, 0.50, or 1.0 mg of ethinylestradiol. Deficiency of antithrombin is known to be associated with an increased risk of thrombosis. Therefore, antithrombin concentrations in blood should be determined before and during treatment with large doses of estrogens.

Key Words: tall stature • height • estrogen • blood coagulation • thrombosis • antithrombin • transcortin

Submitted on June 7, 1982
Accepted on December 30, 1982




This article has been cited by other articles:


Home page
 Arch Pediatr Adolesc MedHome page
D. F. Gunther and D. S. Diekema
Attenuating growth in children with profound developmental disability: a new approach to an old dilemma.
Arch Pediatr Adolesc Med, October 1, 2006; 160(10): 1013 - 1017.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. L. S. Drop, W. J. de Waal, and S. M. P. F. de Muinck Keizer-Schrama
Sex Steroid Treatment of Constitutionally Tall Stature
Endocr. Rev., October 1, 1998; 19(5): 540 - 558.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child.Home page
E Weimann, S Bergmann, and H J Böhles
Oestrogen treatment of constitutional tall stature: a risk-benefit ratio
Arch. Dis. Child., February 1, 1998; 78(2): 148 - 151.
[Abstract] [Full Text]